Back Login to subscribe 🔔 Set Alert

BNTX BioNTech SE American Depositary Share

15 min delay

Loading...

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	BioNTech Stock Dips After BNT122-01 Trial Termination	90.74%
	BioNTech shaes are trading lower after the company announced it will terminate its Phase 2 BNT122-01 trial.	96.33%
	BioNTech Says It Will Terminate Phase 2 BNT122-01 Trial Of Autogene Cevumeran In ctDNA-Positive Resected Colorectal Cancer After DSMB Identified Numerical Overall Survival Imbalance Between Arms; No New Safety Signals	93.17%
	Why Is Arbutus Biopharma Stock Gaining Friday?	83.27%
	BioNTech shares are trading higher. Yesterday, the company announced it will present clinical data from its diversified development program in lung cancer treatment at the IASLC 2026 World Conference on Lung Cancer.	51.54%
	BioNTech Will Present New Data From Its Development Program in Lung Cancer Treatment at the IASLC 2026 World Conference on Lung Cancer In September; Data Highlights Progress Across Pumitamig (BNT327/BMS986545) and Gotistobart (BNT316/ONC-392), As Well As BioNTech’s mRNA-Based Immunotherapy Approaches	79.97%
	Why Is BioNTech Stock Surging on Wednesday?	65.01%
	Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.	94.99%
	Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children	86.07%
	Citigroup Maintains Buy on BioNTech, Lowers Price Target to $125	50.16%

1
2
›